Filing Details

Accession Number:
0001181431-14-007428
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-02-18 18:02:27
Reporting Period:
2014-02-13
Filing Date:
2014-02-18
Accepted Time:
2014-02-18 18:02:27
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
879169 Incyte Corp INCY Services-Commercial Physical & Biological Research (8731) 943136539
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1560782 M James Daly Experimental Station
Route 141 And Henry Clay Rd
Wilmington DE 19880
Evp, Chief Commercial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-02-13 33,333 $18.32 33,333 No 4 M Direct
Common Stock Acquisiton 2014-02-13 6,517 $16.62 39,850 No 4 M Direct
Common Stock Acquisiton 2014-02-13 118,481 $16.62 158,331 No 4 M Direct
Common Stock Disposition 2014-02-13 158,331 $66.49 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2014-02-13 33,333 $0.00 33,333 $18.32
Common Stock Incentive Stock Option (right to buy) Disposition 2014-02-13 6,517 $0.00 6,517 $16.62
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2014-02-13 118,481 $0.00 118,481 $16.62
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
61,209 2020-02-08 No 4 M Direct
11,531 2019-10-21 No 4 M Direct
163,471 2019-10-21 No 4 M Direct
Footnotes
  1. Beginning February 9, 2013, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years.
  2. Beginning October 22, 2012, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years.
  3. Represents weighted average sale price. Actual sales prices ranged from $65.47-$67.41.
  4. Reporting person undertakes to provide upon request by Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares